SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Sep 10, 2007 -- Cytokinetics, Incorporated (NasdaqGM:CYTK - News) announced today that two abstracts related to CK-1827452, a novel small molecule activator of cardiac myosin, will be presented at the 2007 Annual Heart Failure Society of America (HFSA) Meeting in Washington, DC. CK-1827452 is being evaluated in clinical trials for the potential treatment of heart failure and is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc.
